Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4D | Q6B0I6 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | CCR5 | P51681 | 4/20 | 0.41 |
| ▸ | USP30 | Q70CQ3 | 2/20 | 0.41 |
| ▸ | OPRD1 | P41143 | 3/20 | 0.40 |
| ▸ | SLC6A9 | P48067 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.39 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.39 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.39 |
| ▸ | ACHE | P22303 | 1/20 | 0.38 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13778885 | 0.85 | CCR5 (0.47) | KMT2AMEN1CCR5OPRD1SLC6A9 | |
| SCHEMBL4594424 | 0.85 | CCR5 (0.42) | KDM4DKMT2AMEN1CCR5USP30 | |
| SCHEMBL6986421 | 0.82 | HSD11B1 (0.52) | KMT2AMEN1CCR5OPRD1SLC6A9 | |
| SCHEMBL1221934 | 0.82 | KMT2A (0.49) | KMT2AMEN1CCR5OPRD1SLC6A9 | |
| SCHEMBL13215262 | 0.81 | KMT2A (0.43) | KMT2AMEN1CCR5OPRD1SLC6A9 | |
| SCHEMBL13778878 | 0.80 | KMT2A (0.50) | KMT2AMEN1CCR5OPRD1SLC6A9 | |
| SCHEMBL21965410 | 0.80 | GPR119 (0.48) | KDM4DCCR5USP30PDE10A | |
| SCHEMBL15626792 | 0.80 | KMT2A (0.42) | KMT2AMEN1CCR5OPRD1SLC6A9 | |
| SCHEMBL1223309 | 0.80 | CCR5 (0.52) | KMT2AMEN1CCR5OPRD1SLC6A9 | |
| SCHEMBL6794820 | 0.79 | CHRM2 (0.43) | KMT2AMEN1CCR5OPRD1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11180480-B2 | Synthesis of 4-aminopyrimidine compounds | SENSORION (FR) | 2021-11-23 | — | — | US | disclosed |
| US-20200270228-A1 | SYNTHESIS OF 4-AMINOPYRIMIDINE COMPOUNDS | SENSORION (FR) | 2020-08-27 | — | — | US | disclosed |
| WO-2019076974-A1 | SYNTHESIS OF 4-AMINOPYRIMIDINE COMPOUNDS | SENSORION (FR) | 2019-04-25 | — | — | WO | disclosed |
| CN-101903385-B | 4-aminopyrimidine derivatives as histamine H4 receptor antagonists | PALAU PHARMA SA | 2013-11-06 | — | — | CN | disclosed |
| CN-102803248-A | Aminoalkylpyrimidine derivatives as histamine H4 receptor antagonists | PALAU PHARMA SA | 2012-11-28 | — | — | CN | disclosed |
| CN-101903385-A | As histamine H 4The 4-aminopyridine derivative of receptor antagonist | PALAU PHARMA SA | 2010-12-01 | — | — | CN | disclosed |
| EP-1991550-A1 | AMINO PYRIMIDINE COMPOUNDS FOR THE TREATMENT OF INFLAMMATORY DISORDERS | Cellzome Limited (GB) | 2008-11-19 | — | — | EP | disclosed |
| EP-1860109-A1 | Azetidine amino pyrimidine compounds for the treatment of inflammatory disorders | Cellzome (UK) Ltd. (GB) | 2007-11-28 | — | — | EP | disclosed |
| EP-1860109-A1 | Azetidine amino pyrimidine compounds for the treatment of inflammatory disorders | Cellzome (UK) Ltd. (GB) | 2007-11-28 | — | — | EP | disclosed |
| WO-2007090854-A1 | AZETIDINE AMINO PYRIMIDINE COMPOUNDS FOR THE TREATMENT OF INFLAMMATORY DISORDERS | CELLZOME (UK) LTD. (GB) | 2007-08-16 | — | — | WO | disclosed |
| WO-2007090854-A1 | AZETIDINE AMINO PYRIMIDINE COMPOUNDS FOR THE TREATMENT OF INFLAMMATORY DISORDERS | CELLZOME (UK) LTD. (GB) | 2007-08-16 | — | — | WO | disclosed |
| WO-2007090852-A1 | AMINO PYRIMIDINE COMPOUNDS FOR THE TREATMENT OF INFLAMMATORY DISORDERS | CELLZOME LIMITED (GB) | 2007-08-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200270228-A1 | SYNTHESIS OF 4-AMINOPYRIMIDINE COMPOUNDS | KDM5D, KDM5B, KDM4D | KDM4D 3/4885KMT2A 61/4885MEN1 726/4885 |
| US-11180480-B2 | Synthesis of 4-aminopyrimidine compounds | KDM5D, KDM5B, KDM4D | KDM4D 3/4885KMT2A 68/4885MEN1 647/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.